CN103948661B - Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease - Google Patents
Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease Download PDFInfo
- Publication number
- CN103948661B CN103948661B CN201410179268.6A CN201410179268A CN103948661B CN 103948661 B CN103948661 B CN 103948661B CN 201410179268 A CN201410179268 A CN 201410179268A CN 103948661 B CN103948661 B CN 103948661B
- Authority
- CN
- China
- Prior art keywords
- grams
- echinacea
- disease
- pharmaceutical composition
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of pharmaceutical composition and its application for being used to treat gynecological disease, prostatic disorders or anorectal disease.The pharmaceutical composition includes main ingredient and auxiliary material, and main ingredient includes Echinacea element and chitosan.The present invention first applies Echinacea element in externally applied drug, relative to medicine for oral administration, can directly reach diseased region and dosage is less, it is achieved that preferably therapeutic effect；Using the good biocompatibility of chitosan, the effective administration concentration of holding is played to Echinacea element, extends the synergistic effects such as drug treating time, even if Echinacea element is mutually merged with chitosan, and be adsorbed in illing skin or mucomembranous surface formation protective layer；In addition, the defence capability of the generation of glucosaminidase and the growth of fibroblast, lifting skin or mucous membrane can also more effectively be stimulated by being adsorbed in the Echinacea element of skin or mucomembranous surface；Further, Echinacea element can stimulating immune system, increase leucocyte quantity and activity, improve the therapeutic effect of independent medication.
Description
Technical field
The present invention relates to biomedicine field, in particular to one kind be used to treating gynecological disease, prostatic disorders or
The pharmaceutical composition of anorectal disease and its application.
Background technology
The traditional Chinese medical science its " with lower disease " refers mainly to gynaecological disease, and other two class belongs to the " disease below waistband in today's society
Suffer from ", such as prostatosis of male and the anorectal disease that has of men and women, above-mentioned disease is all the vast national common disease of puzzlement, many
Morbidity.Many of which chronic inflammation is referred to as " precancerous lesion ", canceration probability 1.2~3.8%.
The characteristics of above-mentioned each disease is that morbidity is extensive, and the course of disease is long, when it is good when it is bad, be difficult to cure.Although targeted drug is
Number is many, and with obvious drug effect is generally chemical synthetic drug and antibiotics, the production of said medicine and uses
Cheng Zhonghui produces pollution to environment, to patient's toxic side effect, also there is the problem of inducing the resistance to the action of a drug or drug resistance.
Echinacea is that composite family (Asteraceae) genus echinacea (achinacea, also known as Echinacea) plant originates in North America,
It is widely used by the Echinacea of its extraction plain (or Echinacea Purpurea Herb P.E) in US and European, and is generally considered to have and exempts from
Epidemic disease humidification, containing various active composition, can pierce the immunocyte vigor such as leucocyte in human body, improve human body autoimmunity
Power.At present, the main active of the Echinacea element extracted is polyphenol, caffeic acid derivative and polysaccharide, to Echinacea element
Use, or be used in mixed way with other Chinese herbal medicines using the health food for being also substantially used to improve body immunity, as auxiliary
Medicine is used, to after treatment effect.
The content of the invention
The present invention is intended to provide it is a kind of be used for treat gynecological disease, prostatic disorders or anorectal disease pharmaceutical composition and
It is applied, to solve the problem of medicine of gynecological disease, prostatic disorders or anorectal disease in the prior art has toxic side effect.
To achieve these goals, according to an aspect of the invention, there is provided a kind of be used to treat gynecological disease, prostatitis
The pharmaceutical composition of gland disease or anorectal disease, the pharmaceutical composition includes main ingredient and auxiliary material, and main ingredient includes Echinacea element and shell
Glycan.
Further, the formulation of aforementioned pharmaceutical compositions is medical gel.
Further, the content of above-mentioned Echinacea element is 0.02~2.0wt% of pharmaceutical composition, and the content of chitosan is
0.1~5wt% of pharmaceutical composition.
Further, the content of above-mentioned Echinacea element is 0.05~1.0wt% of pharmaceutical composition, and the content of chitosan is
0.5~1.5wt% of pharmaceutical composition.
Further, above-mentioned main ingredient is made up of chitosan and Echinacea element.
Further, above-mentioned medical gel is 2~4ml gel.
Further, above-mentioned auxiliary material includes glycerine, carbomer, EDTA, ethylene glycol, triethanolamine and/or benzoic acid.
According to another aspect of the present invention there is provided a kind of above-mentioned pharmaceutical composition in treatment gynecological disease, prostate
Application in the medicine of disease or anorectal disease.
Further, said medicine be treatment bacterial vaginitis, colpomycosis, Combination vaginitis, cervicitis,
Prostatitis, hypertrophy of the prostate, hyperplasia of prostate, the medicine of internal piles or mixed hemorrhoid.
Apply the technical scheme of the present invention, Echinacea element therein belongs to plant extracts, does not have toxic side effect to human body,
And the present invention first applies Echinacea element in externally applied drug, relative to medicine for oral administration, can directly reach diseased region and dosage
It is less, it is achieved that the therapeutic effect become apparent.The gel of chitosan formation is used as positive charge in pharmaceutical composition
Colloid, can largely be adsorbed, the germ that aggegation is negatively charged, block its metabolic activity and breeding, until disintegration；Meanwhile, utilize shell
The good biocompatibility of glycan, the effective administration concentration of holding is played to Echinacea element, is extended the synergy such as drug treating time and is made
With, mutually merged with chitosan even if Echinacea is plain, and illing skin or mucomembranous surface formation protective layer are adsorbed in, it is therein
Chitosan can prevent the invasion of bacterium and virus, such as suppress, kill the Candida albicans and S. aureus L-forms for being difficult to tackle, moreover it is possible to
It is that epidermal cell and profitable strain provide nutrition, promotes itself to repair and microecological balance；In addition, being adsorbed in skin or mucous membrane table
The Echinacea element in face can not only preferably suppress hyaluronidase activity, blocking virus particle to the attaching of host cell with invading
Enter, and can also more effectively stimulate the generation of glucosaminidase and the growth of fibroblast, promote skin, mucomembranous cell
Nutrition and reparation, lifting skin or mucous membrane defence capability；Further, Echinacea element being capable of stimulating immune system, increase
The quantity and activity of leucocyte, strengthen the phagocytic activity of macrophage, promote lymphokine such as interferon, interleukin, tumour bad
The secretion of necrosis factor, and then improve the therapeutic effect of independent medication.
Embodiment
It should be noted that in the case where not conflicting, the feature in embodiment and embodiment in the application can phase
Mutually combination.The present invention is described in detail below in conjunction with embodiment.
The present invention it is a kind of preferred embodiment in there is provided one kind be used for treat gynecological disease, prostatic disorders or
The pharmaceutical composition of anorectal disease, the pharmaceutical composition includes main ingredient and auxiliary material, and the main ingredient includes Echinacea element and chitosan.
Echinacea element in aforementioned pharmaceutical compositions belongs to plant extracts, does not have toxic side effect, and the present invention to human body
Echinacea element is applied in externally applied drug first, relative to medicine for oral administration, diseased region can be directly reached and dosage is less, therefore
Realize more preferable therapeutic effect.In pharmaceutical composition, the gel of chitosan formation can largely be inhaled as the colloid of positive charge
The negatively charged germ of attached, aggegation, blocks its metabolic activity and breeding, until disintegration；Meanwhile, utilize the good biology of chitosan
Compatibility, the effective administration concentration of holding is played to Echinacea element, extends the synergistic effects such as drug treating time, even if Echinacea is plain
Mutually merged with chitosan, and be adsorbed in illing skin or mucomembranous surface formation protective layer, chitosan therein can be prevented
Bacterium and the invasion of virus, such as suppress, kill and be difficult to the Candida albicans and S. aureus L-forms that tackle, moreover it is possible to for epidermal cell and has
Bacteria group provides nutrition, promotes itself to repair and microecological balance；In addition, the Echinacea for being adsorbed in skin or mucomembranous surface is plain not
It only can preferably suppress the attaching and intrusion of hyaluronidase activity, blocking virus particle to host cell, and can also be more
The generation of glucosaminidase and the growth of fibroblast are effectively stimulated, promotes skin, the nutrition and reparation of mucomembranous cell,
Lift the defence capability of skin or mucous membrane；Further, Echinacea element can stimulating immune system, increase leucocyte quantity and
Activity, strengthens the phagocytic activity of macrophage, promotes the secretion of lymphokine such as interferon, interleukin, TNF, enters
And improve the therapeutic effect of independent medication.
The present invention is directed to the application of pharmaceutical composition, is preferably designed as the formulation of the pharmaceutical composition medical solidifying
Glue.The gel that the further preferred medical gel is 2~4ml.
In addition, passing through long-term biological test and clinic for the aforementioned pharmaceutical compositions especially medical gel present invention
Experiment finds, as the Echinacea element of main ingredient composition and the consumption of chitosan is not to control curative effect in aforementioned pharmaceutical compositions more
Fruit is more obvious, and then it is determined has an amount ranges of good efficacy, and the content of wherein Echinacea element is pharmaceutical composition
0.02~2.0wt%, the content of chitosan is 0.1~5wt% of pharmaceutical composition.
Further, the factor of comprehensive medicinal cost, the absorbability of medicine and the aspect of drug effect three, preferably above-mentioned Echinacea
The content of element is 0.05~1.0wt% of pharmaceutical composition, and the content of chitosan is 0.5~1.5wt% of pharmaceutical composition.
The main ingredient composition of the pharmaceutical composition of the present invention can include the effective component in addition to Echinacea element and chitosan
To realize the application in a variety of disease medicaments are treated, the present invention is preferably applied in this hair with chitosan and Echinacea element for main ingredient
In the medicine of bright treated disease.
The auxiliary material of aforementioned pharmaceutical compositions includes stabilizer and emulsifying agent, and stabilizer and emulsifying agent therein can be used
This area conventional stabilizer and emulsifying agent, such as glycerine, carbomer, EDTA, ethylene glycol, triethanolamine or benzoic acid.
There is provided a kind of aforementioned pharmaceutical compositions in treatment gynaecology disease in another preferred embodiment of the present invention
Application in the medicine of disease, prostatic disorders or anorectal disease.
Said medicine be treatment bacterial vaginitis, colpomycosis, Combination vaginitis, cervicitis, prostatitis,
Hypertrophy of the prostate, hyperplasia of prostate, the medicine of internal piles or mixed hemorrhoid.
Beneficial effects of the present invention are further illustrated below with reference to embodiment and comparative example.
The preparation of pharmaceutical composition：
Embodiment 1
30 grams of chitosans, 8 grams of Acritamer 940s are weighed, 30 grams of Echinacea elements are dissolved in after sterilized water and are poured into emulsion tank respectively,
600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine are added, stirring is allowed to emulsify and gradually plus sterile
Water is until total amount reaches 3000 grams.Then in aseptic subpackaged to 1000 piston type plastic guide pipes, embodiment 1 it is sterile
Gel preparation.
Embodiment 2
6 grams of chitosans, 0.6 gram of Echinacea element, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water is poured into emulsion tank respectively
In, add 600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniform emulsification and gradually
Sterilized water is added until total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the nothing of embodiment 2
Bacterium gel preparation.
Embodiment 3
3 grams of chitosans, 1.5 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water is poured into emulsion tank respectively
In, add 600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniform emulsification and gradually
Sterilized water is added until total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the nothing of embodiment 3
Bacterium gel preparation.
Embodiment 4
45 grams of chitosans, 15 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water is poured into emulsion tank respectively
In, add 600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniform emulsification and gradually
Sterilized water is added until total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the nothing of embodiment 4
Bacterium gel preparation.
Embodiment 5
15 grams of chitosans, 6 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water and is poured into emulsion tank respectively,
600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine are added, stirring is allowed to uniform and emulsifies and gradually add
Enter sterilized water until total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e., embodiment 5 is sterile
Gel preparation.
Embodiment 6
150 grams of chitosans, 60 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water is poured into emulsion tank respectively
In, add 600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniform emulsification and gradually
Sterilized water is added until total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the nothing of embodiment 6
Bacterium gel preparation.
Embodiment 7
1.5 grams of chitosans, 15 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water is poured into emulsion tank respectively
In, add 600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniform emulsification and gradually
Sterilized water is added until total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the nothing of embodiment 7
Bacterium gel preparation.
Comparative example 1
30 grams of chitosans, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water and is poured into emulsion tank respectively, add 600 grams
Glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring be allowed to uniformly emulsify and be gradually added into sterilized water until
Total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the sterile gel preparation of comparative example 1.
Comparative example 2
30 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water and is poured into emulsion tank respectively, add 600
Gram glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniformly emulsify and to be gradually added into sterilized water straight
3000 grams are reached to total amount.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the sterile gel preparation of comparative example 2.
Comparative example 3
150 grams of chitosans, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water and is poured into emulsion tank respectively, add 600 grams
Glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring be allowed to uniformly emulsify and be gradually added into sterilized water until
Total amount reaches 3000 grams.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the sterile gel preparation of comparative example 3.
Comparative example 4
60 grams of Echinacea elements, 8 grams of Acritamer 940s are weighed, is dissolved in after sterilized water and is poured into emulsion tank respectively, add 600
Gram glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, stirring is allowed to uniformly emulsify and to be gradually added into sterilized water straight
3000 grams are reached to total amount.Then it is aseptic subpackaged enter 1000 piston type guiding tubes in, i.e. the sterile gel preparation of comparative example 4.
Found after animal experiment test is carried out to the medicine of above-described embodiment 1 to 7 and comparative example 1 to 4, embodiment 1 to 7
Gel preparation be respectively provided with obvious therapeutic effect to Combination vaginitis, prostatitis and mixed hemorrhoid, and comparative example 1 to 4
Gel preparation does not play obvious therapeutic effect to Combination vaginitis, prostatitis and mixed hemorrhoid, further relates to, this hair
Echinacea element and chitosan in bright pharmaceutical composition serve synergistic function, in treatment gynecological disease, prostate disease
There is good application prospect in the medicine of disease or anorectal disease.
Clinical test
For gynecological disease：
Embodiment 8
Clinically vaginitis, virus in patients with cervicitis, advise and the gel preparation of embodiment 1 are pushed into disease before sleeping every night by totally 240
Become position.7 days as one therapeutic course, therapeutic evaluation is carried out referring next to clinical rating scales, and evaluating result is shown in Table 1.
Table 1
The gel of embodiment 1 is 96.7% to the effective percentage of bacterial vaginitis it can be seen from the data in table 1, mould
The effective percentage of bacterium property vaginitis is 93.3%, and the effective percentage of Combination vaginitis is 98.3%, and the effective percentage of cervicitis is
91.7%, it is 95% to merge total effective rate.
Embodiment 9
Choose clinically vaginitis, virus in patients with cervicitis totally 60.Advise before sleeping every night by 3 grams of the gel preparation of embodiment 2 with
Catheter propelling is to affected part.7 days as one therapeutic course, therapeutic evaluation is carried out referring next to clinical rating scales, and evaluating result is shown in Table 2
Table 2
The gel of the low dosage main ingredient of embodiment 2 is to the effective percentage for mixing vaginitis it can be seen from the data in table 2
50%, the effective percentage of cervicitis is 36.7%, and it is 43.3% to merge total effective rate.
For prostatic disorders：
Embodiment 10
Prostatitis clinically, Patients with Prostatic Hyperplasia, are advised the gel preparation of embodiment 1 before sleeping every night totally by 60
It is pushed into anus deep.7 days as one therapeutic course, therapeutic evaluation is carried out referring next to clinical rating scales, and evaluating result is shown in Table 3.
Table 3
The gel preparation of embodiment 1 is to prostatitic efficient for 90%, prostate it can be seen from the data of table 3
The effective percentage of loose, hyperplasia is 86.6%, and total effective rate is 88.3%.
For anorectal disease：
Embodiment 11
Clinically internal piles, mixed hemorrhoid patient totally 120, advise it to sleep preceding guiding tube every night by the gel preparation of embodiment 1
Anus deep is pushed into, 7 days as one therapeutic course carries out therapeutic evaluation referring next to clinical rating scales, and evaluation result is shown in Table 4.
Table 4
The gel preparation of embodiment 1 is 95% to the effective percentage of internal piles it can be seen from the data in table 4, mixed hemorrhoid
Effective percentage is 93.3%, and total effective rate is 94.2%.
Above-mentioned data are analyzed it can be found that the pharmaceutical composition of the application is in treatment gynecological disease, prostate disease
Obvious therapeutic effect has been played in the medicine of disease or anorectal disease, and the therapeutic effect of embodiment 1 becomes apparent.
The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should be included in the scope of the protection.
Claims (3)
1. a kind of pharmaceutical composition for being used to treat gynecological disease, prostatic disorders or anorectal disease, it is characterised in that the medicine
Compositions are prepared from using following methods：Weigh 30 grams of chitosans, 8 grams of carbomers940, 30 grams of Echinaceas are plain to be dissolved in respectively
It is poured into after sterilized water in emulsion tank, adds 600 grams of glycerine, 30 grams of phenmethylols and 1.5 grams of EDTA and appropriate triethanolamine, is stirred
It is allowed to emulsify and gradually plus sterilized water is until total amount reaches 3000 grams, then aseptic subpackaged to 1000 piston type plastic guide pipes
In.
2. the pharmaceutical composition described in a kind of claim 1 is preparing treatment gynecological disease, prostatic disorders or anorectal disease
Application in medicine.
3. application according to claim 2, it is characterised in that the medicine is treatment bacterial vaginitis, mycotic the moon
The medicine of road inflammation, Combination vaginitis, cervicitis, prostatitis, hypertrophy of the prostate, hyperplasia of prostate, internal piles or mixed hemorrhoid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410179268.6A CN103948661B (en) | 2014-04-29 | 2014-04-29 | Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410179268.6A CN103948661B (en) | 2014-04-29 | 2014-04-29 | Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103948661A CN103948661A (en) | 2014-07-30 |
| CN103948661B true CN103948661B (en) | 2017-08-11 |
Family
ID=51326103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410179268.6A Active CN103948661B (en) | 2014-04-29 | 2014-04-29 | Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948661B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103908479B (en) * | 2014-04-29 | 2017-06-06 | 安徽徽科生物工程技术有限公司 | For treating gynecological disease or dermopathic medical aquogel and its application |
| CN108653356A (en) * | 2018-05-30 | 2018-10-16 | 安徽德睿轩科技服务有限公司 | A kind of pharmaceutical composition and its application for treating anorectal disease |
| CN112156225A (en) * | 2020-11-09 | 2021-01-01 | 唐长菱 | Chitosan or and algal polysaccharide composite biological matrix liquid dressing gel preparation and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973492A (en) * | 2011-09-02 | 2013-03-20 | 欧世文 | Chitosan hydrogel for treating haemorrhoids and preparation method thereof |
| CN103040728A (en) * | 2013-02-03 | 2013-04-17 | 福州乾正药业有限公司 | Chitosan gel for women as well as preparation method and medical application thereof |
-
2014
- 2014-04-29 CN CN201410179268.6A patent/CN103948661B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973492A (en) * | 2011-09-02 | 2013-03-20 | 欧世文 | Chitosan hydrogel for treating haemorrhoids and preparation method thereof |
| CN103040728A (en) * | 2013-02-03 | 2013-04-17 | 福州乾正药业有限公司 | Chitosan gel for women as well as preparation method and medical application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 新兽药紫锥菊根主要活性成分和生理作用分析;李美娣 等;《福建畜牧兽医》;20140120;第36卷(第1期);13-16 * |
| 来自西方的传奇草药-紫锥菊;清源;《医药养生保健报》;20050711;1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103948661A (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948661B (en) | Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN104288727B (en) | A kind of dedicated compound Chinese medicinal preparation of chill cold in children health care | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN102240353A (en) | Traditional Chinese drug anesthetic and preparation method thereof | |
| CN101474284A (en) | External use medicament for treating fungal dermatopathy | |
| CN101439114B (en) | Chinese medicine for treating burn and scald, and preparation method thereof | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| CN103908479B (en) | For treating gynecological disease or dermopathic medical aquogel and its application | |
| CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN108434227A (en) | A kind of drug for treating tinea pedis | |
| CN102302559B (en) | Medicament for treating respiratory system diseases and application thereof | |
| CN104474528A (en) | Medicine used for drainage detoxification | |
| CN108938703A (en) | The gynecological gel of quick antibacterial | |
| CN103948660B (en) | Medical bio bressing suppository and its application for treating gynecological disease, prostatic disorders or anorectal disease | |
| CN107596355A (en) | A kind of Medical pain easing, the exterior-applied gel subsided a swelling, brought down a fever and preparation method thereof | |
| CN103191163B (en) | Skin wound repairing pharmaceutical composition | |
| CN102670735A (en) | Anti-dandruff Chinese medicinal composition and application thereof to anti-dandruff external application agent | |
| CN103041120A (en) | Pharmaceutical composition for controlling chicken infectious bursal disease and preparation method thereof | |
| CN104940547A (en) | Traditional Chinese medicine combination for treating hemorrhoid and preparation technology therefor | |
| CN103272068B (en) | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof | |
| CN109125413A (en) | A kind of Chinese medicinal composition preparation and preparation method thereof with tonifying kidney and strengthening yang effect | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN101474382B (en) | Medicine for treating three major diseases of grass carp | |
| CN100411637C (en) | Chinese animal medicine for treating mammitis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |